1. Leto et al., Supplementary Figure S3
NCI-H508-HER2
NCI-N87 _ 10
0.06
0.12
0.25
0.5
1.25
2.5 5 _ 10
0.06
0.12
0.25
0.5
1.25
2.5 5
TRAS (μg/ml)
LAP (μM)
pHER2
Y1248
HER2
pEGFR
Y1068
EGFR
pHER3
Y1289
HER3
NCI-H508-HER2
NCI-N87 B _ 2 24 48 72 _ 2 24 48 72
TRAS (10 μg/ml) hr
LAP (0.2 μM) hr
pHER2
Y1248
HER2
pEGFR
Y1068
EGFR
pHER3
Y1289
HER3
Supplementary Figure S3. Signaling consequences of treatment with trastuzumab, lapatinib and their combination in HER2-positive colorectal and gastric cancer cells: Duplicate bots for HER receptors
A, Activation status/phosphorylation of HER receptors in NCI-H508-HER2 and NCI-N87 cells in dose-response experiments. Cells were treated with the indicated concentrations of trastuzumab, lapatinib or the combination of both for 2 hours. Cell extracts were immunoblotted with the indicated antibodies. B, Activation status/phosphorylation of HER receptors in NCI-H508-HER2 and NCI-N87 cells in time-course experiments. Trastuzumab, lapatinib or the combination of both were added to cells at the beginning of the experiment at the indicated concentrations. Cells were incubated in the presence of the inhibitor(s) for the indicated times and lysates subjected to Western blot analysis. TRAS, trastuzumab; LAP, lapatinib. See Figure 3A and 3B for a comparison.
Leto et al., Supplementary Figure S3